Tesamorelin Dosage Guide

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release the body's own growth hormone in a more natural, pulsatile pattern. It's best known from clinical research on reducing excess visceral (deep abdominal) fat in a specific patient population. This guide explains how tesamorelin is generally discussed in the literature so you can have a more informed conversation with a qualified clinician.

Important context first: a branded, injectable tesamorelin product has been approved in some regulatory settings for a narrow indication, but the research-grade "tesamorelin" sold through peptide vendors is not an FDA-approved finished drug for general anti-aging, bodybuilding, or fat-loss use. Any use should be supervised by a licensed clinician who can weigh your health history, order labs, and monitor for side effects. Nothing here is a prescription or a substitute for medical advice.

How tesamorelin works

Unlike injecting growth hormone directly, tesamorelin nudges your pituitary to produce and release GH on its own. Because the release stays pulsatile and subject to your body's normal feedback loops, the mechanism is often described as more physiologic than exogenous GH. In studies, the most consistent effect was a reduction in visceral adipose tissue, along with changes in IGF-1 levels that clinicians typically monitor with bloodwork.

Dosing ranges seen in the literature

In the clinical trials that supported tesamorelin's approved indication, the studied dose was 2 mg once daily by subcutaneous injection. That figure is the most commonly cited reference point. Some practitioners and researchers have discussed lower "starter" amounts to gauge tolerance, but there is no universally agreed protocol outside the approved setting, and dosing should never be self-directed.

• Reference research dose: 2 mg subcutaneously, once daily.
• Route: subcutaneous injection, commonly rotated across abdominal sites (avoiding scar tissue and the navel area).
• Cycle length: studies ran for months, and effects on visceral fat were reversible when treatment stopped — meaning benefits generally required ongoing use.

These numbers describe what was studied, not what is right for any individual. A clinician may adjust based on IGF-1 response, tolerance, and goals.

Reconstitution and preparation

Research-grade tesamorelin typically arrives as a lyophilized (freeze-dried) powder that must be reconstituted with a sterile diluent — usually bacteriostatic water — before use. Getting the concentration right is where most dosing errors happen, because the number of "units" on an insulin syringe depends entirely on how much water you add to the vial.

If you're mapping powder-to-liquid math, our reconstitution calculator can help you see how a given amount of diluent translates into a per-injection volume, and the general-purpose peptide calculator is useful for double-checking your intended dose against syringe markings. Always confirm your final plan with the clinician overseeing your care.

Timing and administration

Because growth hormone release is naturally highest during sleep, many protocols in the literature favored dosing in the evening or at bedtime, on an empty stomach, to align with the body's rhythm. Eating a large meal or consuming carbohydrates close to injection is sometimes discussed as blunting the GH pulse, though individual practice varies. Consistency — same time each day — tends to matter more than the exact hour.

Keeping a simple log of doses, timing, and how you feel makes it far easier to spot patterns and share meaningful information with your clinician. A basic dose tracker is a low-effort way to stay organized.

Monitoring and safety

Tesamorelin raises IGF-1, so responsible use in a clinical context usually includes baseline and periodic bloodwork. Commonly reported side effects in trials included injection-site reactions (redness, itching, swelling), joint aches, fluid retention, and occasional changes in blood sugar. Because it affects the GH/IGF-1 axis, people with active cancer, certain pituitary conditions, or during pregnancy are typically excluded from use — another reason clinician oversight is non-negotiable.

• Do not combine peptides or GH-axis compounds without professional guidance.
• Report persistent joint pain, swelling, tingling in the hands, or blood-sugar changes to your clinician.
• Storage matters: keep lyophilized product cool and, once reconstituted, refrigerated and used within the window your clinician or the product guidance specifies.

How tesamorelin differs from GLP-1 medications

People sometimes lump tesamorelin in with popular weight-management injectables, but they work through entirely different pathways. GLP-1 and dual/triple agonists like semaglutide, tirzepatide, and retatrutide act on appetite and metabolic signaling, while tesamorelin works on the growth hormone axis to target visceral fat specifically. If you're comparing options, our broader guides library covers those medications in detail. They are not interchangeable, and each carries its own dosing logic and risk profile.

The bottom line

The most-cited tesamorelin reference dose is 2 mg subcutaneously once daily, studied in a specific medical population and administered under supervision with lab monitoring. Because research-grade tesamorelin is not an FDA-approved finished product for general use, the safest path is a licensed clinician who can evaluate whether it's appropriate, set a plan, and monitor your response. Use this guide to ask better questions — not to self-prescribe.